{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:08:48Z","timestamp":1791576528095,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jaip.2022.05.034","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T22:25:08Z","timestamp":1655504708000},"page":"2025-2038.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Proposed European Competence Network on Mastocytosis\u2014American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis"],"prefix":"10.1016","volume":"10","author":[{"given":"Jason","family":"Gotlib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Shomali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"\u00c1lvarez-Twose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Brockow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Niedoszytko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke Oude","family":"Elberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Siebenhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.05.034_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.05.034_bib2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.05.034_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/asheducation-2018.1.127","article-title":"The new tool \u201cKIT\u201d in advanced systemic mastocytosis","volume":"2018","author":"Shomali","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.jaip.2022.05.034_bib4","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2022.05.034_bib6","series-title":"World Health Organization (WHO) classification of tumours of haematopoietic and lymphoid tissues","first-page":"61","article-title":"Mastocytosis","author":"Horny","year":"2017"},{"key":"10.1016\/j.jaip.2022.05.034_bib7","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"125","author":"Reiter","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib8","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.05.034_bib10","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/leu.2016.190","article-title":"Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.05.034_bib11","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.jaip.2022.05.034_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11899-018-0469-3","article-title":"Clinical validation of KIT inhibition in advanced systemic mastocytosis","volume":"13","author":"Baird","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jaip.2022.05.034_bib13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.05.034_bib14","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.05.034_bib15","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.05.034_bib16","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.05.034_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaip.2022.05.034_bib18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/his.12221","article-title":"CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume":"63","author":"Morgado","year":"2013","journal-title":"Histopathology"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2022.05.034_bib19","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood-2021-146873","article-title":"Efficacy of avapritinib in patients with advanced systemic mastocytosis: hematologic and bone marrow responses from the phase 2 open-label, single-arm, pathfinder study","volume":"138","author":"George","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib20","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","article-title":"Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study","volume":"8","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaip.2022.05.034_bib21","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: mutation-adjusted risk score for advanced systemic mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2022.05.034_bib22","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaip.2022.05.034_bib23","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaip.2022.05.034_bib24","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/mp.53.4.188","article-title":"Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia","volume":"53","author":"Sotlar","year":"2000","journal-title":"Mol Pathol"},{"key":"10.1016\/j.jaip.2022.05.034_bib26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jaip.2022.05.034_bib27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1309\/AJCP1Q0YSXEAHNKK","article-title":"Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22)","volume":"140","author":"Johnson","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jaip.2022.05.034_bib28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41375-018-0346-z","article-title":"KIT D816 mutated\/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis","volume":"33","author":"Jawhar","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.05.034_bib29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/17474086.2014.955008","article-title":"The serum tryptase test: an emerging robust biomarker in clinical hematology","volume":"7","author":"Valent","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jaip.2022.05.034_bib30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/modpathol.2011.84","article-title":"Evaluation of the WHO criteria for the classification of patients with mastocytosis","volume":"24","author":"S\u00e1nchez-Mu\u00f1oz","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaip.2022.05.034_bib31","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1016\/j.jaip.2021.08.001","article-title":"Assessment of osteoporosis and fracture risk in mastocytosis within a North American cohort","volume":"9","author":"Makovoz","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.05.034_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jaip.2022.05.034_bib33","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.05.034_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","article-title":"Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis","volume":"64","author":"Greiner","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.jaip.2022.05.034_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaip.2022.05.034_bib36","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.6004\/jnccn.2018.0088","article-title":"Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Gotlib","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jaip.2022.05.034_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib38","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.21.01849","article-title":"Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis","volume":"40","author":"L\u00fcbke","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2022.05.034_bib39","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.2021012694","article-title":"Frequency and prognostic impact of blood circulating tumor mast cells in mastocytosis","volume":"139","author":"Henriques","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.22526","article-title":"Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis","volume":"57","author":"Naumann","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jaip.2022.05.034_bib41","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/ajh.25265","article-title":"Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases","volume":"93","author":"Shah","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.05.034_bib42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.05.034_bib43","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.05.034_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106606","article-title":"Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)","volume":"108","author":"Taylor","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2022.05.034_bib45","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.jaip.2021.02.040","article-title":"Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: prompt resolution of anaphylaxis with the addition of avapritinib","volume":"9","author":"Kudlaty","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.05.034_bib46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2022.05.034_bib47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2010.01407.x","article-title":"A\u00a0critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions","volume":"84","author":"Pardanani","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaip.2022.05.034_bib48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib49","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jaip.2022.05.034_bib50","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.3390\/ijms22062983","article-title":"Response criteria in advanced systemic mastocytosis: evolution in the era of KIT inhibitors","volume":"15","author":"Shomali","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2022.05.034_bib51","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/bloodadvances.2019000152","article-title":"A\u00a0phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis","volume":"3","author":"Gotlib","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2022.05.034_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-137413","article-title":"Pure pathologic response is associated with improved overall survival in patients with advanced systemic mastocytosis receiving avapritinib in the phase I EXPLORER study","volume":"136","author":"Gotlib","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib53","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2022.05.034_bib54","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaip.2022.05.034_bib55","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","article-title":"Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jaip.2022.05.034_bib56","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib57","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib58","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2022.05.034_bib59","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.05.034_bib60","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events. Version 4.03. Accessed January 9, 2022. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"10.1016\/j.jaip.2022.05.034_bib63","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2022.05.034_bib64","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2021-150872","article-title":"Effective control of advanced systemic mastocytosis with avapritinib: mutational analysis from the EXPLORER clinical study","volume":"138","author":"Deininger","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib65","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2022.05.034_bib66","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib67","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.05.034_bib68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood.2020008466","article-title":"What your H\u03b1T says about you","volume":"137","author":"Gotlib","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.05.034_bib69","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebiom.2019.03.089","article-title":"Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis","volume":"43","author":"Grootens","year":"2019","journal-title":"EBioMedicine"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822005852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822005852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:34:18Z","timestamp":1761975258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822005852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2213219822005852"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.05.034","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proposed European Competence Network on Mastocytosis\u2014American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}